Revumenib “has showed anticancer effects and possible signs of resistance,” according to scientists at the University of Texas and the Dana Farber Cancer Institute.
This hopeful drug managed to total disappearance of cancerous signs in 30% of people in clinical trial.
Revumenib, used to fight off advanced or resistant acute myeloid leukemia, has reached some remission degree in 53% of patients and complete remission in 30%.
The clinical trial found “the inhibition of a menin protein by revumenib produced encouraging responses in advanced acute leukemias with KMT2A or mutant NPM1 rearrangements”.
Experts warned of the emergence of selective resistance to menin inhibition.
The specialists identified specific mutations in MEN1 gene (encoding menin), which can lead to revumenib treatment resistance by altering the drug binding site.
Acute leukemia is usually characterized by mutation of the nucleophosmin 1 (NPM1) gene or rearrangement of the mixed-lineage leukemia 1 (KMT2Ar) gene, both of which have been shown to contribute to cancer progression.